Rigel Pharmaceuticals’ R343 inhaled SYK inhibitor has failed to meet primary or secondary endpoints in a Phase 2 study, the company said. As a result, Rigel will discontinue development of the product for the treatment of asthma.
Rigel Chairman and CEO James M. Gower said, “This was not the result we expected based on the collection of data we had previously seen with R343 in this therapeutic area. Fortunately, we have a robust portfolio of clinical and preclinical research programs to focus on that includes Fostamatinib, R333 for discoid lupus erythematosus and R348 for dry eye. We will be reviewing our portfolio and will discuss these plans in the near-term,” he added.
Read the Rigel press release.
